Our integrated design, prototyping, and sequencing-based analytics help teams make better decisions at every stage of RNA therapeutic development. Contact us to learn how Eclipsebio can support your program, whether you need targeted expertise or a full lab-in-the-loop solution.
Contact usEnd-to-End RNA Therapeutic Support
Eclipsebio delivers end-to-end RNA therapeutic solutions that help developers design, evaluate, and advance RNA medicines with confidence. By integrating AI-driven design, rapid RNA prototyping, and deep sequencing analytics, we shorten development timelines, reduce risk, and support successful translation from discovery to scale.
RNA development tailored to your needs
Eclipsebio supports RNA therapeutic programs at any stage. Teams can engage across the full closed loop of design, make, and test to rapidly iterate and optimize candidates using integrated AI, RNA prototyping, and sequencing-based analytics. For teams with existing capabilities, we plug in where needed, whether that is design-only optimization, testing-only characterization, or connecting you with validated manufacturing partners for scale-up. This flexible approach enables faster decisions, reduced risk, and confident progress toward the clinic.
Talk to an RNA expertDevelop with confidence
Eclipsebio supports RNA drug development across the full lifecycle, working with teams from early-stage startups to global biopharma. Our integrated design, prototyping, and analytics capabilities enable confident decisions and reduced risk at every stage of development
Optimize RNAs for what matters
Traditional RNA design approaches often optimize for a single objective, such as yield or expression, creating downstream tradeoffs in stability and performance. eNAVIGATE applies multi-objective optimization using machine learning models trained on over 29,000 data points to balance manufacturability, expression, and stability for your specific target product profile.
Compare design tradeoffs across multiple performance dimensions. Four sequence designs for the same protein are shown, each tailored for a specific goal such as increased manufacturability or increased protein production.
Prototype fast. Scale with confidence.
We have optimized our in-house capabilities to support rapid RNA prototyping, including challenging constructs such as linear mRNAs greater than 5 kb. This enables fast, iterative design cycles until the optimal candidate is identified. Once a lead is selected, our network of validated manufacturing partners supports efficient and reliable scale-up.
Example fragment analyzer trace from an in-house RNA construct, demonstrating high yield and integrity suitable for iterative design and validation.
Unparalleled resolution for RNA quality
Our sequencing-first approach to RNA characterization and quality control provides actionable insights into RNA therapeutic biology that are not accessible with traditional assays. From identifying the precise sources of dsRNA impurities to mapping the effects of LNP formulation on RNA stability, our platform delivers the resolution needed to support confident development decisions.
This plot shows dsRNA levels across an RNA sequence, highlighting regions that contribute to dsRNA formation. Line thickness and color indicate each base’s relative contribution to dsRNA generation.
What our
partners say
"Eclipsebio’s analysis of RNA folding has provided valuable insights necessary to understand the impact of RNA sequence and chemical modifications on secondary structures…to help improve the design of our RNAs and rationalize our internal findings."
"At Acuitas we are interested in how modifications to LNP formulations can impact efficacy and stability. Eclipsebio’s eSHAPE assay has potentially revealed direct correlations between LNP composition and RNA secondary structure, further adding to our understanding of the mechanism of action for RNA-LNP systems."